PNS236 COMPARATIVE ANALYSIS OF TRANSPARENCY COMMITTEE OPINION CONCERNING THE MEDICAL BENEFIT OBTAINED BY DRUGS AVAILABLE IN EARLY ACCESS PROGRAM VS THE OTHERS IN FRANCE
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.2136
https://www.valueinhealthjournal.com/article/S1098-3015(19)34514-0/fulltext
Section Title :
Section Order :
11851
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)34514-0&doi=10.1016/j.jval.2019.09.2136